All In Biotech

Drug Trial Radar · NCT04708314

An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy

An Open-Label Study to Evaluate the Safety of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

2

Actual

Start

Oct 31, 2020

Primary completion

May 13, 2021

Study completion May 13, 2021

Sponsor

Lead sponsor
Rare Disease Research, LLCAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sarepta Therapeutics, Inc.
First posted
Jan 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label study to evaluate the safety and tolerability of golodirsen injection in Non-ambulant DMD patients with confirmed genetic mutations amenable to treatment by exon 53 skipping (Golodirsen). Golodirsen 30 mg/kg will be administered as an intravenous (IV) infusion over approximately 35 to 60 minutes once a week during the treatment period (up to 96 weeks). After the treatment period, patients can go into a safety extension period (not to exceed 48 weeks) until the patient is able to transition to commercially available drug or a separate golodirsen study. Safety will be regularly assessed throughout the study via the collection of adverse events (AEs), laboratory tests, electrocardiograms (ECGs), echocardiograms (ECHOs), vital signs, and physical examinations. Exploratory assessments, including pulmonary function tests (PFTs), upper extremity testing, and other measurements of functional status, will occur at functional assessment visits every 12 weeks over the first year of treatment and approximately every 24 weeks over the second year of treatment.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]Drug

    Vyondys 53

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Explore the safety and tolerability of Golodirsen in number of participants with Treatment Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: Baseline up to 96 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Rare Disease Research, LLC

    Atlanta, Georgia

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.